PAPER Switzer AR, Charidimou A, McCarter S, Vemuri P, Nguyen AT, Przybelski SA, Lesnick TG, Rabinstein AA, Brown RD, Knopman DS, Petersen RC, Jack CR Jr, Reichard RR, Graff-Radford J
SEARCH RESULTS
331873 RESULTS
PAPER Minokoshi Y, Kim YB, Peroni OD, Fryer LG, Müller C, Carling D, Kahn BB
Editorial Expression of Concern: Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase.
Nature. 2024 May 6; PubMed: 38710933PAPER Egle M, Deal JA, Walker KA, Wong DF, Sharrett AR, Gottesman RF
Association between retinal microvascular abnormalities and late-life brain amyloid-β deposition: the ARIC-PET study.
Alzheimers Res Ther. 2024 May 6;16(1):100. PubMed: 38711107PAPER Prins ND, de Haan W, Gardner A, Blackburn K, Chu HM, Galvin JE, Alam JJ
Phase 2A Learnings Incorporated into RewinD-LB, a Phase 2B Clinical Trial of Neflamapimod in Dementia with Lewy Bodies.
J Prev Alzheimers Dis. 2024;11(3):549-557. PubMed: 38706271Brent Burket
Asante Medford, United States
Eppendorf & Science Prize for Neurobiology
GRANT Monday, May 6, 2024- 1:30pm Eppendorf and Science magazine $25,000, publication of the winning essay in Science, and financial support for travel to the awards ceremony (held in conjunction with the meeting of the Society for Neuroscience). Open to early
Sarah Perrau
Whites Valley, Australia
Gilbert Di Paolo on Might SORL1 Bind Tau in Glia, Fuel Its Aggregation?
COMMENT Cooper et al. report interesting findings consistent with the notion that SORL1 may operate as an intracellular receptor for internalized tau, in a process that modulates tau seeding and may thus be relevant for tau spreading in AD. While there is mountin
Jeffrey Dage on In ADAD, Plaque Removal Improves Synaptic and Inflammatory Biomarkers
COMMENT In this study by Wagemann et. al, gantenerumab and solanezumab have been studied in the context of dominantly inherited Alzheimer disease (DIAD), and they have shown different effects on downstream biomarkers. Previously reported results (Salloway et al.,
PAPER Kaur I, Behl T, Sehgal A, Singh S, Sharma N, Aleya L, Bungau S
Correction to: Connecting the dots between mitochondrial dysfunction and Parkinson's disorder: focus mitochondria-targeting therapeutic paradigm in mitigating the disease severity.
Environ Sci Pollut Res Int. 2024 May 6; PubMed: 38705926PAPER Daly T, Kurkinen M
Measuring our language about anti-amyloid antibodies in Alzheimer's disease: Technical, theoretical, and lay language considerations.
Clin Neurol Neurosurg. 2024 Apr 30;241:108314. PubMed: 38703469PAPER Kaur D, Behl T, Chigurupati S, Sehgal A, Singh S, Sharma N, Badavath VN, Vargas-De-La-Cruz C, Bhatia S, Al-Harrasi A, Dey A, Aleya L, Bungau S
Correction to: Deciphering the focal role of endostatin in Alzheimer's disease.
Environ Sci Pollut Res Int. 2024 May 6; PubMed: 38705927PAPER Aameri R, Ghorbani H, Reza Bazrafshan H, Zahra Gharib F, Korani B
Retraction notice to "Iranian thyme honey plays behavioral, cellular and molecular important roles as an amazing preventive and therapeutic agent in the brain of Alzheimer's rat model" [Neurosci. Lett. 783 (2022) 136702].
Neurosci Lett. 2024 May 4;:137793. PubMed: 38705795PAPER Qiu N, Qian C, Guo T, Wang Y, Jin H, Yao M, Li M, Guo T, Lv Y, Si X, Wu S, Wang H, Zhang X, Xia J
Discovery of a novel chemotype as DYRK1A inhibitors against Alzheimer's disease: Computational modeling and biological evaluation.
Int J Biol Macromol. 2024 May 2;:132024. PubMed: 38704072PAPER Kuang Y, Zhu M, Gu H, Tao Y, Huang H, Chen L
Alkaloids in Uncaria rhynchophylla improves AD pathology by restraining CD4+ T cell-mediated neuroinflammation via inhibition of glycolysis in APP/PS1 mice.
J Ethnopharmacol. 2024 May 3;331:118273. PubMed: 38703874Current Filters
No filters selected